Reimagining the condom for comfort, safety and sensation
A next-generation hydrogel condom designed for enhanced feel and hypoallergenic performance underwent a Phase 1 pilot with 35 couples. Results confirmed safety, efficacy, and strong user preference—setting up larger trials and scaled manufacturing.
Within those who use contraceptives, condoms are the second most popular option behind female sterilization. The first rubber condom was produced in 1855 and has dominated the Sexual and Reproductive Health and Wellness industry since. Eudaemon believe that the limitations of a traditional rubber condom – odor, taste, and allergic reactions are yet to be addressed by solutions in the market. This is why they’re developing a next-generation condom that people will be excited to use.
Termed ‘Project Geldom’, they’ve developed a condom that uses a tough hydrogel material mimicking skin. This provides enhanced feel, self-lubrication, customizable sensations, and hypoallergenic performance compared to conventional latex. Their goal is to build a medical-grade condom and to prove this they worked with Mobius for their Phase 1 pilot clinical trial.
Mobius designed and ran a trial involving 35 couple participants. The initial results have been yielded strong results for safety, efficacy, and consumer preference. Furthermore it set Eudaemon up with advanced preparation for a pivotal trial (>200 couples and 1,000 uses), and scalable manufacturing in partnership with Bosch and CSIRO.
Eudaemon want to disrupt a US $11B condom market by building a condom people can’t wait to try. This would revolutionise safe sex, enhance family planning, and sexual health strategies while saving healthcare agencies millions worldwide.
At Mobius, we are experts at taking innovations from blueprint to breakthrough, together. If you have an innovation that can advance care – reach out.
Key outcomes
- Phase 1 pilot trial with 35 couples completed successfully
- Demonstrated strong safety, efficacy, and consumer preference
- Hydrogel condom material offered enhanced feel and hypoallergenic performance
- Prepared foundation for pivotal trial (>200 couples, 1,000 uses)
- Supported scalable manufacturing with Bosch and CSIRO partnerships
- Positioned to disrupt the US $11B condom market with next-generation technology